- Home
- APTO vs SILO Comparison
APTO vs SILO Comparison
Compare APTO & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APTO
- SILO
- Stock Information
- Founded
- APTO 1986
- SILO 2010
- Country
- APTO Canada
- SILO United States
- Employees
- APTO N/A
- SILO N/A
- Industry
- APTO Biotechnology: Biological Products (No Diagnostic Substances)
- SILO Apparel
- Sector
- APTO Health Care
- SILO Consumer Discretionary
- Exchange
- APTO Nasdaq
- SILO Nasdaq
- Market Cap
- APTO 7.2M
- SILO 5.9M
- IPO Year
- APTO N/A
- SILO N/A
- Fundamental
- Price
- APTO $0.39
- SILO $1.06
- Analyst Decision
- APTO Strong Buy
- SILO
- Analyst Count
- APTO 3
- SILO 0
- Target Price
- APTO $6.00
- SILO N/A
- AVG Volume (30 Days)
- APTO 70.7K
- SILO 150.8K
- Earning Date
- APTO 11-08-2024
- SILO 11-12-2024
- Dividend Yield
- APTO N/A
- SILO N/A
- EPS Growth
- APTO N/A
- SILO N/A
- EPS
- APTO N/A
- SILO N/A
- Revenue
- APTO N/A
- SILO $72,102.00
- Revenue This Year
- APTO N/A
- SILO $1.86
- Revenue Next Year
- APTO N/A
- SILO N/A
- P/E Ratio
- APTO N/A
- SILO N/A
- Revenue Growth
- APTO N/A
- SILO N/A
- 52 Week Low
- APTO $0.33
- SILO $0.84
- 52 Week High
- APTO $2.91
- SILO $4.50
- Technical
- Relative Strength Index (RSI)
- APTO 50.13
- SILO 47.77
- Support Level
- APTO $0.36
- SILO $1.05
- Resistance Level
- APTO $0.41
- SILO $1.35
- Average True Range (ATR)
- APTO 0.02
- SILO 0.12
- MACD
- APTO -0.00
- SILO -0.00
- Stochastic Oscillator
- APTO 43.33
- SILO 37.14
About APTO Aptose Biosciences Inc.
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.